GlassScriptPhysician profile
Mary A Browning
NPI 1477615649
$750.75
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $732 · 2022: $18.31.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $149.50 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.22 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.49 | 2021 | |
| Abbvie INC. | $98.53 | 2021-2022 | |
| Lundbeck LLC | $70.77 | 2021 | |
| Sunovion Pharmaceuticals INC. | $68.84 | 2021 | |
| Eisai INC. | $35.75 | 2021 | |
| Vanda Pharmaceuticals INC. | $25.37 | 2021 | |
| Merck Sharp & Dohme LLC | $18.08 | 2021 | |
| Neos Therapeutics, LP | $16.46 | 2021 | |
| Array Biopharma INC | $13.74 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.